MIMEDX GROUP, INC.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
MDXG$3.37+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity – For the years ended
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands, except share data)
| Common Stock · AdditionalPaid-in · Treasury Stock · Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Shares | Amount | Deficit | Total | |
| Balance at December 31, 2022 | 113,705,447 | $114 | $173,804 | — | $— | $(191,906) | $(17,988) |
| Share-based compensation expense | — | — | 17,178 | — | — | — | 17,178 |
| Restricted stock shares canceled/forfeited | — | — | 378 | 90,367 | (378) | — | — |
| Exercise of stock options | 130,129 | — | 885 | (17,032) | 112 | — | 997 |
| Employee stock purchase plan | 444,809 | — | 1,367 | — | — | — | 1,367 |
| Issuance of restricted stock | 2,185,604 | 2 | (268) | (73,335) | 266 | — | — |
| Repurchase of Series B Preferred Stock | — | — | (4,935) | — | — | — | (4,935) |
| Conversion of Series B Preferred Stock | 29,761,650 | 30 | 87,840 | — | — | — | 87,870 |
| Net income | — | — | — | — | — | 58,228 | 58,228 |
| Balance at December 31, 2023 | 146,227,639 | $146 | $276,249 | — | $— | $(133,678) | $142,717 |
| Share-based compensation expense | — | — | 16,933 | — | — | — | 16,933 |
| Employee stock purchase plan | 245,640 | — | 1,582 | — | — | — | 1,582 |
| Exercise of stock options | 207,686 | — | 1,397 | — | — | — | 1,397 |
| Shares received in settlement of litigation | (1,200,000) | (1) | (9,299) | — | — | — | (9,300) |
| Issuance of restricted stock, net | 1,451,067 | 2 | (2,643) | — | — | — | (2,641) |
| Net income | — | — | — | — | — | 42,419 | 42,419 |
| Balance at December 31, 2024 | 146,932,032 | $147 | $284,219 | — | $— | $(91,259) | $193,107 |
| Issuance of restricted stock, net | 882,093 | 1 | (3,119) | — | — | — | (3,118) |
| Share-based compensation expense | — | — | 16,396 | — | — | — | 16,396 |
| Employee stock purchase plan | 279,795 | — | 1,585 | — | — | — | 1,585 |
| Net income | — | — | — | — | — | 48,578 | 48,578 |
| Balance at December 31, 2025 | 148,093,920 | $148 | $299,081 | — | $— | $(42,681) | $256,548 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.